期刊文献+

IL-6受体mRNA反义寡核苷酸抑制骨吸收的体外研究 被引量:2

Inhibitory effect of IL-6 receptor mRNA antisense oligonucleotide on mouse bone resorption
下载PDF
导出
摘要 目的 :探讨IL 6RmRNA特异反义寡核苷酸 (ASON)在体外对骨吸收的影响及意义。方法 :采用器官培养法培养新生的小鼠颅盖骨 ,并分别用ASON、无义寡核苷酸 (NSO)、IL 6或ASON与IL 6联合处理颅盖骨 ,未加药组为对照。培养一定时间后 ,测定培养上清液的钙含量 ,将实验组钙含量与对照组钙含量比值作骨吸收指数。结果 :作用 4 8h后 ,不同剂量的ASON均可轻度降低骨吸收指数 ,但无剂量依赖关系 ,ASON(5 μmol/L)对正常培养的颅盖骨的骨吸收的抑制率为 8.6 % ;用IL 6培养颅盖骨使骨吸收指数呈剂量依赖关系升高 ,ASON(5 .0 μmol/L)可能明显抑制由IL 6 (4 0μg/L)引起的高骨吸收指数 ,其抑制率为 5 8.0 % ;NSO对骨吸收指数无影响。ASON(5 .0 μmol/L)分别作用 1 2、2 4、4 8h的骨吸收指数则随时间延长而降低。结论 :ASON阻断IL 6R表达后明显抑制IL 6刺激所致的新生小鼠颅盖骨骨吸收 。 Objective:To study the effect of interleukin 6 receptor(IL 6R)mRNA antisense oligonucleotide(ASON)on bone resorption.Methods:Calvaria of newborn mice were cultured,and then exposed to ASON,nonsense oligonucleotide(NSO),IL 6 and IL 6 plus ASON.Calcium concentration of supernatant was determined by atomic absorption spectrophotometry.Bone absorption index(BAI)was defined as the ratio of calcium level in experimental group to that in control group.Results:ASON treatment led to the mild decrease of BAI.but NSO had no obvious influence on BAI.IL 6 treatment resulted in dose dependent increase of BAI,Treated with ASON at the concentration of 5 μmol/L,the inhibition rates of bone absorption for calvarium culture with or without IL 6 were 58% and 8.6% respectively;furthermore,BAI decrease was in a time dependent manner.Conclusion:IL 6R mRNA ASON is via blocking IL 6R expression to inhibit significantly bone absorption of IL 6 stimulated calvarium culture,but its inhibition for bone absorption of normal calvarium culture is mild.
出处 《广东医学院学报》 2003年第5期425-427,共3页 Journal of Guangdong Medical College
基金 广东医学院青年基金 (970 1 )
关键词 IL-6 IL-6受体 反义寡核苷酸 骨吸收 IL 6 IL 6 receptor antisense oligonucleotide bone absorption
  • 相关文献

参考文献10

  • 1任娟,董蕾,徐仓宝,潘伯荣,李明众,王晖,王晓丽,王梅.KDR反义寡核苷酸对人胃癌细胞的作用[J].第四军医大学学报,2002,23(4):333-336. 被引量:11
  • 2张炜真,于世凤,郑麟蕃.用作骨吸收研究的小鼠颅盖骨器官培养方法[J].中华口腔医学杂志,1996,31(1):48-50. 被引量:5
  • 3Smythe MD,Imran MD,Mustafa MD,et al Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product [J]. Thorac Cardiovasc Surg, 2002,123:1191-1198.
  • 4Jhang HP,Yefim M,Han S K,et al. An antisense oligonucleotide to 1-cys peroxiredoxin causes lipid peroxidation and apoptosis in lung epithelial cells [J]. Biol Chem, 2002,27(51) :49927-49934.
  • 5Lin SC,Yamate T,Taguchi Y, et al. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex sterios in murin bone marrow [J]. Clin Invest, 1997,100(8):1980-1990.
  • 6Yasuda H,Shima N, Nakagawa N,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL [J]. Proc Natl Acad Sci USA, 1998, 95: 3597-3605.
  • 7Obricen CA, Gubrij I,Lin SC,et al. STAT activation in stromal/osteoblast cell is required for induction of the receptor activate of NF-Kappa B ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokine or inter-leukin-1 but not 1,25-dihydroxyritamineD3 or parathyroid hormone[J]. J Biol Chem, 1999,274(27) :19301-19308.
  • 8Yokoshiki H, Sunagawa M, Takashi S, et al. Antisense oligodeoxynucleotides of sulfonylurea receptors inhibitATP-sensitive K^+ channels in cultured neonatal rat ventricular cells [J]. Pflügers Arch Eur Physiol. 1999, 437:400-408.
  • 9Mumdy GR, Boyce BF, Yoneda T, et al. Cytokines and bone remodeling [M]//In: Marcurs R, Fldman Dkelsey J(eds). Osteoporosis. California: Academic Press, 1996.301-313.
  • 10Matin TJ,Udagawa N. Hormonal regulation of osteoblast function [J]. TEM, 1998,9 : 6-13.

二级参考文献3

共引文献13

同被引文献45

  • 1曾天舒,陈璐璐,夏文芳,黎慧清,周慜.雌激素对大鼠去卵巢后白细胞介素-6介导的骨吸收的影响[J].中华老年医学杂志,2005,24(1):53-56. 被引量:2
  • 2李楠,林旭,王和鸣,郑良朴,林一萍,沈霖,周琳瑛,钟秀容,林芳.IL-6影响骨髓基质细胞凋亡机理的初步探讨[J].中国骨质疏松杂志,2005,11(1):12-16. 被引量:7
  • 3屠冠军,安贵峰,马立学.核因子与白细胞介素-6在骨质疏松模型中的表达特征[J].中华实验外科杂志,2005,22(9):1091-1093. 被引量:1
  • 4Scheidt-Nave C, Bismar H, Leidig-Bruckner G, etal. Serum interleukin-6 is a major predictor of bone loss in woman specific to the first decade past menopause[J]. J Clin Endocrinol Metab, 2001, 86:2032-2042.
  • 5Manolagas SC. The role of IL-6 type cytokines and their receptors in bone[J]. Ann N Y Acad Sci, 1998, 840:194-204.
  • 6Quaedackers ME, Van Den Brink CE, Wissink S, et al. 4-hydroxy-tamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta[J]. Endocrinology, 2001, 142(3): 1156-1166.
  • 7Helen Brady, Mary Doubleday, Leah M, et al. Differential response of estrogen receptors a and β to SP500263, a novel potent selective estrogen receptor modulator[J]. Mol Pharmacol, 2002,8(3):562-568.
  • 8Ozmen B, Kirmaz C, Aydin K, et al. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-betal and bone turnover markers in the treatment of postmenopausal osteoporosis[J]. Eur Cytokine Netw, 2007, 18(3): 148-153.
  • 9Chae H J, Chae SW, Chin HY, et al. The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts[J]. Bone, 2001, 28:45-53.
  • 10Jia C. Dai, Ping He, Xin Chen, et al. TNF-a and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics[J]. Bone, 2006, 38:509-520.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部